BIO vs GMED
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 21, 2026
BIO
GMED
Investment Advisor Scores
GMED
AI Analyst Insights
Detailed Metrics Comparison
| Metric | BIO | GMED | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 38.61 | 18.9036 | GMED |
| PEG Ratio | 1.1905 | 1.7253 | BIO |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | -0.1% | 5.9% | GMED |
| Earnings Growth | 18.7% | -26.2% | BIO |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 37.1/100 | 31.9/100 | BIO |
| Profit Margin | 8.6% | 17.0% | GMED |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | EXTENDED | SELL | BIO |
Relative Price Performance (Last 90 Days)
Current Technical Phase
BIO
MarkupPrice above SMA50, rising 50-day trend (7.9% over 20 days), RSI 78
GMED
MarkupPrice above SMA50, rising 50-day trend (1.4% over 20 days), RSI 61
Fundamentals Snapshot
| Metric | BIO | GMED |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 37.9 | 16.2 |
| Trailing P/E | 44.4 | 22.5 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.1% |
| Gross Margin | 0.5% | 0.7% |
| Operating Margin | 0.1% | 0.2% |
| EPS | 8.47 | 3.80 |
| Dividend Yield | — | — |